Hepatocellular carcinoma (HCC) · line 1 · Sorafenib monotherapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-SORAFENIB-MONO`

ID	`IND-HCC-SYSTEMIC-1L-SORAFENIB`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-NCCN-HCC-2025`

Notes

Most-accessible 1L for Ukraine; lenvatinib non-inferior alternative when accessible.

Used By

Algorithms

ALGO-HCC-SYSTEMIC-1L - ALGO-HCC-SYSTEMIC-1L
ALGO-HCC-SYSTEMIC-2L - ALGO-HCC-SYSTEMIC-2L